Mateon | HealthWire
Mateon Therapeutics
Keeping an eye on Mateon Therapeutics (OTCQB: MATN) says GEN - Genetic Engineering & Biotechnology News - EmergingGrowth.com
Windlas Biotech, Mateon Therapeutics bring lung therapy food supplement PulmoHeal - FFOODS Spectrum - Unleashing the Power of Food Science & Technology
Articles about Mateon Therapeutics, Inc.
MATEON'S C001- A GLOBAL PHASE 2 STUDY FOR OT-101 AGAINST
Mateon Therapeutics Announces Termination of FOCUS Study in
Mateon Therapeutics Company Profile: Valuation, Investors, Acquisition | PitchBook
Windlas Biotech and Mateon Therapeutics Launch India's First Combined Lung Therapy and Ai Telemedicine 360 Solution to Transform Respiratory Wellness - The Pharma Times | Pharma & Health Care News Portal
A Covid-19 treatment plan slowly emerges | Evaluate
Windlas Biotech and Mateon Therapeutics launch first-ever Drug-Device Lung Therapy Combined AI 360 platform for respiratory wellness - The Statesman
EDGAR Filing Documents for 0001493152-21-001207
Mateon Therapeutics (MATN) expands its management team to accelerate the commercialization and development of OT-101 for COVID-19 - EmergingGrowth.com
Mateon and PointR to merge into AI-driven oncology firm
Mateon launches antiviral programme focussed on Covid-19
Mateon Completes Its Acquisition of PointR Data Inc. - DATAVERSITY
Zacks Small-Cap Research
MATN: Positive Early Results for ARTIVeda™ in Treating COVID-19…
DEVELOPMENT UPDATE FOR ARTIVEDA™/ARTISHIELD™ AGAINST
Blockchain-Fueled Company Mateon Develops Phase 3 Clinical Drug Candidate, Against COVID-19 - OT-101 – Blockchain News, Opinion, TV and Jobs
NantCell Binding Termsheet | MATEON THERAPEUTICS INC | Business Contracts | Justia
Windlas Biotech and Mateon Therapeutics to launch combined lung therapy, AI Telemedicine solution - Express Healthcare
Mateon Therapeutics
Windlas Biotech, Mateon Therapeutics launch drug-device plus lung therapy platform - Express Pharma
